<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318058</url>
  </required_header>
  <id_info>
    <org_study_id>104540</org_study_id>
    <nct_id>NCT00318058</nct_id>
  </id_info>
  <brief_title>Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population</brief_title>
  <official_title>A Phase I/II, Open, Controlled Study in Order to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals Influenza Candidate Adjuvanted Vaccine in an Elderly Population Aged Over 65 Years Previously Vaccinated in 2004 With the Same Candidate Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      As influenza vaccine efficacy is reported to be lower in elderly subjects compared to healthy&#xD;
      adults, probably as a result of immunosenescence, there is a desire to devise ways to&#xD;
      increase the current vaccines efficacy for this target population. Adjuvants are known to&#xD;
      boost immune responses, thus representing one way to increase the efficacy of the current&#xD;
      GlaxoSmithKline Fluarix™ influenza vaccine in elderly subjects. The purpose of this study is&#xD;
      to evaluate the immunogenicity and the reactogenicity of a revaccination with the adjuvanted&#xD;
      GlaxoSmithKline influenza vaccine administered intramuscularly about 1 year after&#xD;
      administration of the first dose of vaccine. For immunogenicity and safety evaluations,&#xD;
      subjects who have already received Fluarix™ during the preceeding year will receive a dose of&#xD;
      commercial vaccine and will form the control group of this trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2005</start_date>
  <completion_date type="Actual">November 4, 2005</completion_date>
  <primary_completion_date type="Actual">November 1, 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage, intensity and relationship to vaccination of local (at the injection site) and general signs and symptoms during a 21 day follow-up period after vaccination</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events during the entire study.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of the humoral immune response (haemagglutinin antibody titre) and cellular mediated immune response</measure>
  </secondary_outcome>
  <enrollment type="Actual">84</enrollment>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza vaccine Fluarix, Adjuvanted Fluarix</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A male or female aged over 65 years at the time of the revaccination; who previously&#xD;
             received the adjuvanted candidate vaccine or Fluarix during a clinical study organized&#xD;
             during the preceeding year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug or vaccine) other than the&#xD;
             study vaccine(s) within 30 days preceding the administration of the study vaccine, or&#xD;
             planned use during the study period.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other&#xD;
             immune-modifying drugs within six months prior to the administration of the study&#xD;
             vaccine.&#xD;
&#xD;
          -  History of confirmed influenza infection since a year from the date of previous&#xD;
             vaccination.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination&#xD;
&#xD;
          -  History of hypersensitivity to vaccines.&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine.&#xD;
&#xD;
          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional&#xD;
             abnormality, as determined by physical examination or laboratory screening tests.&#xD;
&#xD;
          -  Acute disease at the time of enrolment.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the three months&#xD;
             preceding the administration of the study vaccine or during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>April 25, 2006</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2006</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>104540</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104540</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104540</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104540</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104540</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104540</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

